Repros Therapeutics (RPRX) Announces FDA Meeting to Discuss Phase 3 Efficacy Studies of Androxal
Go back to Repros Therapeutics (RPRX) Announces FDA Meeting to Discuss Phase 3 Efficacy Studies of Androxal| REPROS THERAPEUTICS (NASDAQ: RPRX) | Delayed: 61.33 +0.02 (0.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $61.31 | 52 Week High | $3.48 | |||
| Open | $61.19 | 52 Week Low | $0.80 | |||
| Day High | $61.54 | P/E | N/A | |||
| Day Low | $60.80 | EPS | $-1.54 | |||
| Volume | 2,357,860 | |||||
